Nothing said here yet.
to join the conversation.
| Monges VivianeDirector | Sell | 11,969 | $395.5K | Wed, Sep 23 |
| Schikan Johannes Gerardus Christiaan PetrusDirector | Sell | 800 | $29.0K | Tue, Sep 22 |
| Nassif David W.CFO / CLO | Sell | 6,000 | $218.8K | Mon, Sep 21 |
| Schikan Johannes Gerardus Christiaan PetrusDirector | Sell | 200,000 | $7.0M | Thu, Sep 17 |
| Lu PengPresident | Sell | 100,000 | $3.5M | Thu, Sep 17 |
| Bjork ElisabethDirector | Sell | 52,500 | $2.0M | Thu, Sep 17 |
| Lesage AnneChief Early Development | Sell | 20,000 | $765.5K | Thu, Sep 17 |
| Glassman RobertDirector | Sell | 14,493 | $558.8K | Thu, Sep 17 |
| Abele Stefan AndreasChief Technical Ops Officer | Sell | 45,000 | $1.7M | Tue, Sep 15 |
| Glassman RobertDirector | Sell | 8,667 | $331.7K | Tue, Sep 15 |
| Souverijns WimChief Commercial Officer | Sell | 6,090 | $237.4K | Tue, Sep 15 |
| Abele Stefan AndreasChief Technical Ops Officer | Sell | 1,400 | $54.9K | Tue, Sep 15 |
BofA sees the recent dip in PHVS’s share price as a buying chance ahead of two big FDA decisions in 2027.
Pharvaris recently reported that a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme, covering 1,131 patients and 225 physicians across the US, Europe, and Japan, has been published in Advances in Therapy,…
Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention.
Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial.
Pharvaris (PHVS) could gain greater market share in hereditary angioedema with its deucrictibant ext
The company will seek approval for deucrictibant XR as competition in the HAE market mounts.
Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.
Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline results from its pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant XR for the prevention of hereditary angioedema attacks.